We are pleased to award, for the fifth time internationally, the Medical Nutrition Scholarship Award to PKU patients and other metabolic disorder sufferers.

The scholarship is intended to help people with metabolic disorders such as phenylketonuria (PKU) and tyrosinemia (TYR), who are facing the challenges in vocational training and access to further education or their professional development through training, courses and apprenticeships.

During the course of 2023, POA Pharma GmbH, a subsidiary of POA Pharma Scandinavia AB and of the pharmaceutical company Galen LTD from Northern Ireland, launched its first products for the benefit of PKU patients.

In the years 2023 and 2024, two scholarships have already been awarded successfully. We are pleased to inform you that in 2025 one scholarship each for Germany and Austria will be awarded.

The Scholarship

The lucky winners will receive a grant of up to € 2,500 to support their studies/training courses and, depending on individual needs, of electronic teaching aids up to a value of €2,000.

Who can apply?

In Germany as well as in Austria, anyone can apply for the sponsorship award who is undergoing treatment for a diagnostically confirmed metabolic disorder – such as phenylketonuria (PKU), tyrosinemia (TYR), maple syrup urine disease (MSUD), urea cycle disorder (UCD) or homocystinuria (HCU).

For a scholarship to be awarded, a confirmed diagnosis must first be available from a licensed physician. Applicants must already have identified a recognized university, technical college or a training course provider, before the scholarship is awarded; however, they can apply before their acceptance has been confirmed by the respective institution.

If successful applicants have already paid their course/semester fees for the upcoming teaching block before the award ceremony, the costs can be reimbursed up to the maximum amount. Otherwise, the fees up to the maximum will be paid directly in the name of the of the prizewinner to the provider of the tuition.

How to apply?

To enter, please use the link: www.poapharma.de/scholarship/

Please complete the application form including a personal statement (1000 words or less) describing how this scholarship will enable you to achieve your personal and career goals. The personal statement can be submitted in Microsoft Word format.

Applications are open now and the closing date for entries is 5 pm (CET) on Monday 1st September 2025. Award winners will be notified by 5 pm (CET) on Friday 26th September 2025.

The Medical Nutrition Awards committee, which will include representatives from the metabolic disease community, will evaluate entries and select the winners based on their written entry, aspirations, and commitment to study.

# ENDS #

About POA Pharma GmbH

POA Pharma GmbH focuses on the distribution, marketing, and commercialisation of proprietary, generic, and rare disease products, bringing German patients selected products and services of POA Pharma Scandinavia AB.

Founded in 2023, it is committed to doing all it can to improve the lives and benefit the health of all generations affected by a variety of diseases.

POA Pharma GmbH benefits from being part of the wider POA Pharma network, providing the resources to help deliver high quality products and services to German patients.

Based in Copenhagen, POA Pharma Scandinavia AB, the parent company of POA Pharma GmbH, works every day to be of value to patients with inborn metabolic diseases (IMDs) and to their caregivers, offering POA products for Phenylketonuria (PKU) as well as for several other IMDs, which are currently available in the UK, Sweden, Norway, Denmark and Finland and the USA.

POA Pharma is part of Galen Limited, a privately owned company established in 1968, with global headquarters in Craigavon, Northern Ireland, and commercial operations based in the UK, Ireland, the Nordics, Europe, and the USA. With global partners in every continent, it is positioned to distribute products worldwide.

Galen Limited was founded in Northern Ireland by the late Sir Allen McClay (d. 2010), the revered philanthropist and entrepreneur, and has since become the proud founding member of the Almac Group

With 6600+ employees and 18 facilities globally, the Almac Group is now owned by the McClay Foundation, whose overarching aim is to make a meaningful improvement and advancement in human health.